[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Chiayi Christian Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":103},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100615469","a-study-on-the-effectiveness-of-olive-oil-mouthwash-in-alleviating-chemoradiotherapy-induced-oral-mucositis-in-patients-with-head-and-neck-cancer-100615469",false,"NCT07293013","A Study on the Effectiveness of Olive Oil Mouthwash in Alleviating Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer.","Inclusion Criteria:\n\n* A. Aged 20 years or older. B. Diagnosed with a primary cancer located in the head and neck region and preparing to undergo radiotherapy or concurrent chemoradiotherapy (CCRT). For the purposes of this study, CCRT is defined as receiving chemotherapy within one week before or after the first day of radiotherapy.\n\nC. The total prescribed radiotherapy dose is between 6000 and 7200 cGy. D. Conscious and able to communicate in Mandarin or Taiwanese. E. Willing to participate in the study after receiving an explanation, and capable of signing the informed consent form.\n\nExclusion Criteria:\n\nA. Patients diagnosed with recurrent head and neck cancer undergoing a second course of radiotherapy or CCRT.\n\nB. Patients who are allergic or have a history of allergy to any component of the intervention used in this study.\n\nC. Patients who are unable to open their mouth due to skin grafting. D. Patients with known metastasis (M1). E. Patients who have already developed oral mucositis (OM). F. Patients with skin diseases, autoimmune disorders, or those deemed unsuitable for the study by the physician.","ALL","20 Years",{"count":18,"type":19},120,"ESTIMATED","INTERVENTIONAL",[22],"NA","Backgroud: Radiation therapy and concurrent chemoradiotherapy are the main treatment methods for patients with head and neck cancer, which often lead to many severe oral mucositis (OM). It is easy to cause dry mouth and infection, which seriously affects the comfort and quality of life of patients. There are many pharmacological and non-pharmacological mouthwash solutions in clinical practice, the purpose of which is to reduce bacterial accumulation in order to prevent and improve OM. Olive oil has powerful moisturizing, antioxidant and anti-inflammatory properties. There is no research on the use of olive oil in the prevention or treatment of OM.\n\nObjective: The purpose of this study was to evaluate the preventive and therapeutic effects of olive oil as a mouthwash solution on OM caused by radiation therapy or concurrent chemoradiotherapy.\n\nMethods: The research design of this study is a randomized controlled trial. Patients from a radiation oncology clinic of a regional teaching hospital in southern China were invited to participate in the study by intentional sampling. The study will be followed for 12 weeks and will collect data before and after treatment with olive oil mouthwash or standard care. Assessment tools include demographic characteristics, severity of OM (RTOG and OMAS), degree of dry mouth (XQ and Saxon test), pain severity(VAS), Shortened General Comfort Questionnaire (SGCQ) and head and neck cancer patients quality of life scale (FACT-H\\&N). The research data will be statistically analyzed by SPSS 22.0 statistical software, and the statistical significance is defined as the P value less than 0.05 as the significant level. Statistical methods include 1) Descriptive statistics include times, percentages, averages, standard deviations, etc. 2) Inferential statistics: Chi-square test, independent t-test, paired t-test and Logistic regression were used to compare the post-test data between the experimental group and the control group, and to detect the effectiveness of intervention measures and 3) Using generalized estimating equations (GEE) to predict the effect of interventions (repeated measures) on OM severity, dry mouth, body weight, quality of life and comfort scores.\n\nExpected outcomes: This study aimed to investigate the efficacy of gargling with olive oil in reducing the incidence of OM, severity of OM, severity of dry mouth, severity of pain, and improved patient comfort and quality of life.",[25,26],"Oral Mucositis in Head and Neck Cancer","Chemo-radiotherapy",[28,29,26],"Oral Mucositis","Head and Neck Cancer","RECRUITING","2025-12-15",{"date":33,"type":34},"2025-12-18","ACTUAL",{"date":36,"type":34},"2022-12-04",{"date":38,"type":19},"2026-12",{"name":40,"class":41},"Chiayi Christian Hospital","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":20,"phases":53,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100579415","phase-4-prevention-and-treatment-for-bruises-in-patients-with-ischemic-stroke-100579415","NCT06823999","Prevention and Treatment for Bruises in Patients With Ischemic Stroke","Effect of Vitamin C in the Prevention and Treatment for Bruises in Patients With Ischemic Stroke: A Double-blind Randomized Control Trial","Inclusion Criteria:\n\n* Ischemic stroke patients.\n* Aged 20 to 85 years.\n\nExclusion Criteria:\n\n* o Cancer patients undergoing chemotherapy.\n\n  * End-stage renal disease patients receiving hemodialysis.\n  * Patients undergoing immunosuppressive therapy.\n  * Patients with coagulation disorders.\n  * Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency (favism).\n  * Patients with thalassemia.\n  * Patients who did not sign the consent form.","85 Years",{"count":52,"type":19},400,[54],"PHASE4","Background Over the past few decades, significant advances have been made in the diagnosis and treatment of strokes. Most studies focus on functional recovery in stroke patients. In addition to motor function, there are many symptoms may affect function and quality of life in stroke patients. Bruises are caused by damage to the skin that causes blood to drain out of the capillaries and accumulate in the connective tissue of the skin or subcutaneous tissue. The study on non-motor syndrome in ischemic stroke patients found that 25.8% of ischemic stroke patients had bruises and 17.7% of bruises were unexplained bruises. In addition to the physiological and emotional effects on stroke patients, bruises may increase infection risk and affect stroke patient outcomes. Vitamin C is a natural antioxidant discovered in 1747 to treat and prevent scurvy. Vitamin C can reduce gum bleeding and prevent colon bleeding after a polypectomy. Vitamin C has been reported to reduce brain edema around brain injury and decrease mortality in patients with traumatic brain injury. Dehydroascorbic acid decreases infarct volume in mice with middle cerebral artery occlusion. Investigators hypothesized that administration of vitamin C to patients with acute ischemic stroke patients would decrease the risk of bleeding and enhance its resolution. Investigators also hypothesized that vitamin C injection could minimize infarct volume and improve outcomes in ischemic stroke patients. The aims of the study include: 1. To investigate whether vitamin C injections can reduce bruising risk and enhance bruising resolution. 2. To explore whether vitamin C injections in the acute phase of stroke can improve the prognosis of ischemic stroke patients.\n\nMethods This is a prospective, double-blind, randomized controlled study. All patients admitted to the hospital under the diagnosis of ischemic stroke and stroke was confirmed by Magnetic Resonance imaging (MRI) or brain computed imaging (CT) and aged between 20 and 85 years were invited to participate in the study. Investigators excluded patients who had these diseases: cancer receiving chemotherapy, end stage renal disease receiving dialysis, autoimmune disease, hematological disease, Glucose-6-phosphatase disease, gouty arthritis, and a lack of informed consent.\n\nDuring the study period, all patients who met the inclusion and exclusion criteria were invited to participate in the study. After informed consent, participants were randomly assigned to the experimental group or the control group. All participants underwent NIHSS evaluation and a detailed dermatological examination on the day of hospitalization. After enrollment, the experimental group received 4 mg Vitamin C injection per day for 4 days, while the control group received the same volume of normal saline injection per day for 4 days. Researchers evaluate participant skin condition (including bruises number and size, color) every day during hospitalization, and up to 1 month after stroke. Investigators evaluate NIHSS at discharge and follow-up functional outcome (mRS) up to 3 months after stroke onset.\n\nAnalysis Rate shows bruise percentage. Chi square or Fisher exact test was applied to compare the difference in bruises between two groups. Logistic regression was used to compare bruise risk between groups. Wilcoxon rank sign test was used to analyze stroke severity and outcome between two groups.",[57,58,59],"Stroke","Bruises","Skin Lesions",[61,62,63,64,65],"stroke","bruises","skin lesions","vitamin C","bleeding","NOT_YET_RECRUITING","2025-02-11",{"date":69,"type":34},"2025-02-13",{"date":71,"type":19},"2025-08-01",{"date":73,"type":19},"2028-07-31",{"name":40,"class":41},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":15,"minAge":84,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":20,"phases":87,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":4},"100575616","effects-of-nonpharmacological-interventions-in-sleep-quality-anxiety-and-delirium-for-patients-of-adult-intensive-care-units-100575616","NCT06774599","Effects of Nonpharmacological Interventions in Sleep Quality, Anxiety, and Delirium for Patients of Adult Intensive Care Units","Effects of Nonpharmacological Interventions in Sleep Quality, Anxiety, and Delirium for Patients of Adult Intensive Care Units: a Randomized Controlled Trial","Sleep","Inclusion Criteria:\n\n* Conscious and able to speak or write (GCS ≥ 11)\n* Hemodynamically stable\n* Normal hearing and able to communicate in a low voice\n* Stay in ICU for more than 24 hours\n* Aged over 18 years.\n\nExclusion Criteria:\n\n* Pre-existing insomnia diagnosis with long-term reliance on sleep medication,\n* Sleep-related medical history such as sleep apnea\n* Shift work prior to hospitalization\n* Diagnosis of alcohol abuse or schizophrenia\n* End-of-life or terminal conditions\n* Allergy to essential oils\n* Exclusion of dementia",true,"18 Years",{"count":86,"type":19},154,[22],"This study will investigate the effect of nonpharmacological intervention in sleep quality, anxiety and delirium among adult ICU patients.",[90,91,92,93,94],"Intensive Care Unit","Critical Care","Sleep Quality","Anxiety","Delirium","2025-01-12",{"date":97,"type":34},"2025-01-14",{"date":99,"type":19},"2025-03-14",{"date":101,"type":19},"2025-10-09",{"name":40,"class":41},""]